Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

COYACoya Therapeutics, Inc.

Nasdaq · CIK 0001835022
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts152

Identity from submissions API

NameCoya Therapeutics, Inc.
CIK0001835022
TickersCOYA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone650.739.3939
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
12645 MEMORIAL DR., SUITE F1 #305
HOUSTON
TX
77024
TX
Mailing address
12645 MEMORIAL DR., SUITE F1 #305
HOUSTON
TX
77024
TX

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

232 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-10 10-Q 10-Q 0001193125-26-454478 001-41583 261538060 34 7504496 1 1
2026-11-10 8-K 8-K 2.02,9.01 0001193125-26-454473 001-41583 261538042 34 453829 1 1
2026-10-14 8-K 8-K 8.01 0001193125-26-421066 001-41583 261458360 34 148432 1 1
2026-10-05 8-K 8-K 8.01 0001193125-26-413218 001-41583 261438859 34 146439 1 1
2026-09-15 8-K 8-K 8.01 0001193125-26-391378 001-41583 261379182 34 146827 1 1
2026-08-11 10-Q 10-Q 0001193125-26-343481 001-41583 261260698 34 7156664 1 1
2026-08-11 8-K 8-K 2.02,9.01 0001193125-26-343473 001-41583 261260686 34 452607 1 1
2026-08-07 8-K/A 8-K/A 5.02 0001193125-26-340449 001-41583 261255206 34 146568 1 1
2026-07-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-034737 005-93853 261203443 34 9358
2026-06-25 8-K 8-K 5.07 0001193125-26-282989 001-41583 261122834 34 146113 1 1
2026-05-13 ARS ARS 0001193125-26-220695 001-41583 26971079 34 2924296
2026-05-13 DEFA14A DEFA14A 0001193125-26-220690 001-41583 26971063 34 644957
2026-05-13 DEF 14A DEF 14A 0001193125-26-220688 001-41583 26971056 34 1981197 1 1
2026-05-12 8-K 8-K 1.01,9.01 0001193125-26-218282 001-41583 26966044 34 464848 1 1
2026-05-12 424B5 424B5 0001193125-26-218278 333-289511 26966036 33 458070
2026-05-12 10-Q 10-Q 0001193125-26-218201 001-41583 26965900 34 6586754 1 1
2026-05-12 8-K 8-K 2.02,8.01,9.01 0001193125-26-218198 001-41583 26965896 34 453035 1 1
2026-04-09 4 4 0001193125-26-149968 5281
2026-04-09 3 3 0001193125-26-149960 14991
2026-04-02 8-K 8-K 5.02,9.01 0001193125-26-139094 001-41583 26830788 34 240811 1 1
2026-03-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-000895 333-294315 26779757 33 1733
2026-03-20 424B3 424B3 0001193125-26-117738 333-294315 26778613 33 230864
2026-03-19 CORRESP filename1.htm 0001193125-26-115931 5316
2026-03-19 UPLOAD filename1.pdf 0000000000-26-002775 333-294315 40051
2026-03-16 S-3 S-3 0001193125-26-107413 333-294315 26754760 33 429129 1 1
2026-03-16 10-K 10-K 0001193125-26-107281 001-41583 26754552 34 29865077 1 1
2026-03-16 8-K 8-K 2.02,9.01 0001193125-26-107276 001-41583 26754544 34 462322 1 1
2026-03-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001575872-26-000104 005-93853 26747168 34 12459
2026-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000083 005-93853 26581897 34 7046
2026-01-30 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-26-030531 001-41583 26580592 34 457409 1 1
2026-01-28 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-26-003978 005-93853 26571528 34 9281
2026-01-26 4 4 0001193125-26-021729 5440
2026-01-26 4 4 0001193125-26-021728 5493
2026-01-26 4 4 0001193125-26-021725 5483
2026-01-26 4 4 0001193125-26-021724 5468
2026-01-20 8-K 8-K 8.01 0001193125-26-016017 001-41583 26541195 34 139696 1 1
2026-01-08 8-K 8-K 8.01 0001193125-26-007042 001-41583 26517490 34 144226 1 1
2026-01-06 4 4 0001193125-26-005024 5199
2026-01-06 4 4 0001193125-26-005023 5224
2026-01-06 4 4 0001193125-26-005022 5171
2026-01-06 4 4 0001193125-26-005018 5143
2026-01-06 4 4 0001193125-26-005015 5175
2025-12-17 8-K 8-K 8.01 0001193125-25-321737 001-41583 251577275 34 139495 1 1
2025-11-12 10-Q 10-Q 0001193125-25-276058 001-41583 251469162 34 7542951 1 1
2025-11-12 8-K 8-K 2.02,7.01,9.01 0001193125-25-276022 001-41583 251469093 34 451308 1 1
2025-10-27 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-25-250709 001-41583 251417487 34 558069 1 1
2025-10-27 424B5 424B5 0001193125-25-250699 333-289511 251417478 33 553218
2025-10-23 424B5 424B5 0001193125-25-248847 333-289511 251413558 33 553469
2025-09-02 8-K 8-K 8.01 0001193125-25-193450 001-41583 251283089 34 140617 1 1
2025-08-19 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002680 333-289511 251233721 33 1734
2025-08-19 424B7 424B7 0001193125-25-183460 333-289511 251232230 33 359107
2025-08-19 4 4 0001641172-25-024820 6897
2025-08-18 CORRESP filename1.htm 0001193125-25-182618 6351
2025-08-13 UPLOAD filename1.pdf 0000000000-25-008542 333-289511 40099
2025-08-12 S-3 S-3 0001193125-25-178531 333-289511 251204180 33 1375367 1 1
2025-08-12 10-Q 10-Q 0000950170-25-106934 001-41583 251204134 34 7162790 1 1
2025-08-12 8-K 8-K 2.02,7.01,9.01 0000950170-25-106932 001-41583 251204131 34 459059 1 1
2025-07-29 8-K 8-K 8.01 0001193125-25-168115 001-41583 251162910 34 140036 1 1
2025-07-01 8-K 8-K 8.01 0001193125-25-153465 001-41583 251094193 34 139894 1 1
2025-06-26 8-K 8-K 5.07 0001193125-25-149104 001-41583 251081154 34 147341 1 1
2025-05-16 ARS ARS 0001193125-25-121800 001-41583 25960467 34 53607434
2025-05-16 DEFA14A DEFA14A 0001193125-25-121786 001-41583 25960391 34 221332
2025-05-16 DEF 14A DEF 14A 0001193125-25-121779 001-41583 25960307 34 2107533 1 1
2025-05-13 10-Q 10-Q 0000950170-25-069824 001-41583 25937281 34 6488760 1 1
2025-05-13 8-K 8-K 2.02,7.01,9.01 0000950170-25-069819 001-41583 25937249 34 458838 1 1
2025-04-28 10-K/A 10-K/A 0001193125-25-100816 001-41583 25881469 34 887469 1 1
2025-03-18 10-K 10-K 0000950170-25-040782 001-41583 25746560 34 25100475 1 1
2025-03-18 8-K 8-K 2.02,7.01,9.01 0000950170-25-040779 001-41583 25746558 34 477528 1 1
2025-02-25 4 4 0000950170-25-027255 5134
2025-02-25 4 4 0000950170-25-027254 5158
2025-02-25 4 4 0000950170-25-027253 5038
2025-02-25 4 4 0000950170-25-027252 5130
2025-02-25 4 4 0000950170-25-027251 5102
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000929638-25-000790 005-93853 25629465 34 12436
2025-02-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-005549 005-93853 25603767 34 9551
2025-01-30 S-8 S-8 0001193125-25-017337 333-284609 25574680 33 64945
2025-01-13 4 4 0000950170-25-004575 5184
2025-01-13 4 4 0000950170-25-004573 5230
2025-01-13 4 4 0000950170-25-004572 5252
2025-01-13 4 4 0000950170-25-004571 5189
2025-01-03 4 4 0000950170-25-001571 5080
2025-01-03 4 4 0000950170-25-001570 5144
2025-01-03 4 4 0000950170-25-001569 5176
2025-01-03 4 4 0000950170-25-001568 5200
2025-01-03 4 4 0000950170-25-001567 5172
2024-11-29 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-29 16:00:00 9999999995-24-003622 333-283366 241517287 33 1741
2024-11-29 424B3 424B3 0001193125-24-268100 333-283366 241516542 33 232941
2024-11-26 CORRESP filename1.htm 0001193125-24-266104 5792
2024-11-25 UPLOAD filename1.pdf 0000000000-24-013046 333-283366 40030
2024-11-20 S-3 S-3 0001193125-24-262623 333-283366 241481338 33 319742
2024-11-14 4 xslF345X05/ownership.xml 0001493152-24-046106 4495
2024-11-13 4 xslF345X05/ownership.xml 0001493152-24-045120 4544
2024-11-12 4 xslF345X05/ownership.xml 0001493152-24-044896 4562
2024-11-12 4 xslF345X05/ownership.xml 0001493152-24-044819 4543
2024-11-12 SC 13G/A UnitedStates_13G__CoyaTherap.txt 0000932471-24-001003 005-93853 241447468 34 6515
2024-11-06 10-Q 10-Q 0000950170-24-121837 001-41583 241429319 34 5782492 1 1
2024-11-06 8-K 8-K 2.02,7.01,9.01 0000950170-24-121833 001-41583 241429297 34 437980 1 1
2024-11-05 8-K 8-K 5.02 0001193125-24-251319 001-41583 241428421 34 147227 1 1
2024-11-04 SC 13G/A UnitedStates_13G__CoyaTherap.txt 0000932471-24-000368 005-93853 241422182 34 5593
2024-11-04 SC 13G/A UnitedStates_13G__CoyaTherap.txt 0000932471-24-000408 005-93853 241421654 34 5593
2024-10-31 8-K 8-K 5.02,9.01 0001193125-24-248755 001-41583 241415809 34 277632 1 1
2024-10-29 8-K 8-K 7.01,9.01 0001193125-24-246171 001-41583 241402731 34 2622276 1 1
2024-10-28 D xslFormDX01/primary_doc.xml 06b 0001493152-24-042710 021-527969 241401621 33 15358
2024-10-22 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-24-240775 001-41583 241384830 34 493033 1 1
2024-08-20 3 xslF345X02/ownership.xml 0001493152-24-033261 14799
2024-08-19 8-K 8-K 5.02,7.01,9.01 0001193125-24-202551 001-41583 241218411 34 238114 1 1
2024-08-12 10-Q 10-Q 0000950170-24-095075 001-41583 241194813 34 5630195 1 1
2024-08-12 8-K 8-K 2.02,7.01,9.01 0000950170-24-095072 001-41583 241194792 34 436156 1 1
2024-07-15 8-K 8-K 8.01 0001193125-24-178809 001-41583 241115795 34 148085 1 1
2024-06-24 424B3 424B3 0001193125-24-167085 333-280235 241065491 33 247452
2024-06-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-06-21 17:00:00 9999999995-24-001918 333-280235 241061879 33 1741
2024-06-20 CORRESP filename1.htm 0001193125-24-164441 5237
2024-06-18 UPLOAD filename1.pdf 0000000000-24-006981 333-280235 40271
2024-06-14 S-3 S-3 0001193125-24-161701 333-280235 241045775 33 350022
2024-06-05 4 4 0000950170-24-069551 5164
2024-06-05 4 4 0000950170-24-069550 5236
2024-06-05 4 4 0000950170-24-069549 5231
2024-06-05 8-K 8-K 1.01,9.01 0001193125-24-154729 001-41583 241020788 34 163194 1 1
2024-05-20 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-24-142950 001-41583 24965501 34 550377 1 1
2024-05-09 10-Q 10-Q 0000950170-24-057056 001-41583 24931150 34 4862479 1 1
2024-05-09 8-K 8-K 2.02,7.01,9.01 0000950170-24-057018 001-41583 24931028 34 392611 1 1
2024-05-08 8-K 8-K 5.02,5.07,9.01 0001193125-24-134376 001-41583 24927584 34 173088 1 1
2024-03-29 DEFA14A DEFA14A 0000950170-24-038250 001-41583 24801053 34 749640
2024-03-28 ARS ARS 0000950170-24-038118 001-41583 24799793 34 2895088
2024-03-28 DEFA14A DEFA14A 0000950170-24-038112 001-41583 24799715 34 824334
2024-03-28 DEF 14A DEF 14A 0000950170-24-038090 001-41583 24799555 34 812359
2024-03-19 10-K 10-K 0000950170-24-033161 001-41583 24761165 34 13162014 1 1
2024-03-19 8-K 8-K 2.02,7.01,9.01 0000950170-24-033159 001-41583 24761161 34 438350 1 1
2024-03-05 4 xslF345X05/ownership.xml 0001493152-24-008916 5047
2024-02-14 SC 13G/A AMENDMENT NO. 1 0000929638-24-000705 005-93853 24639650 34 81668
2024-02-07 SC 13G/A formsc13ga.htm 0001493152-24-005327 005-93853 24606307 34 104516
2024-02-02 4 xslF345X05/ownership.xml 0001493152-24-004813 7732
2024-02-02 4 xslF345X05/ownership.xml 0001493152-24-004815 5313
2024-02-02 4 xslF345X05/ownership.xml 0001493152-24-004814 5417
2024-01-19 4 xslF345X05/ownership.xml 0001493152-24-003109 5385
2024-01-19 4 xslF345X05/ownership.xml 0001493152-24-003111 5410
2024-01-19 4 xslF345X05/ownership.xml 0001493152-24-003110 5293
2024-01-19 4 xslF345X05/ownership.xml 0001493152-24-003108 5389
2024-01-19 4 xslF345X05/ownership.xml 0001493152-24-003107 5413
2024-01-19 8-K 8-K 8.01 0001193125-24-010775 001-41583 24543788 34 153867 1 1
2024-01-16 424B3 424B3 0001193125-24-008554 333-276374 24535205 33 478234
2024-01-12 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-01-12 17:00:00 9999999995-24-000119 333-276374 24533471 33 1740
2024-01-10 CORRESP filename1.htm 0001193125-24-006011 5292
2024-01-09 UPLOAD filename1.pdf 0000000000-24-000304 333-276374 40296
2024-01-04 S-3 S-3 0001193125-24-002488 333-276374 24512795 33 573885
2024-01-04 4 xslF345X05/ownership.xml 0001493152-24-001080 5366
2023-12-29 3 xslF345X02/ownership.xml 0001493152-23-046474 10590
2023-12-20 D xslFormDX01/primary_doc.xml 06b 0001493152-23-045524 021-500218 231499679 33 14096
2023-12-20 8-K 8-K 5.02,7.01,9.01 0001193125-23-299370 001-41583 231499457 34 175137 1 1
2023-12-12 SC 13G sch13g.htm 0000929638-23-003417 005-93853 231481241 34 116591
2023-12-06 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-23-289550 001-41583 231468421 34 1077393 1 1
2023-11-08 10-Q 10-Q 0000950170-23-060718 001-41583 231386253 34 5795459 1 1
2023-11-08 8-K 8-K 2.02,7.01,9.01 0000950170-23-060716 001-41583 231386246 34 386464 1 1
2023-08-21 4 FORM 4 SUBMISSION 0000899243-23-018335 5138
2023-08-21 3 FORM 3 SUBMISSION 0000899243-23-018334 6241
2023-08-21 8-K 8-K 5.02,7.01,9.01 0001193125-23-217039 001-41583 231189854 34 174173 1 1
2023-08-08 10-Q 10-Q 0000950170-23-039354 001-41583 231149280 34 6161978 1 1
2023-08-08 8-K 8-K 2.02,7.01,9.01 0000950170-23-039348 001-41583 231149260 34 403812 1 1
2023-07-19 4 xslF345X05/ownership.xml 0001493152-23-024969 5422
2023-07-19 3 xslF345X02/ownership.xml 0001493152-23-024968 9728
2023-07-14 8-K 8-K 5.02,9.01 0001193125-23-187328 001-41583 231089695 34 208496 1 1
2023-07-10 8-K 8-K 5.02,9.01 0001193125-23-184752 001-41583 231080503 34 202851 1 1
2023-06-29 8-K 8-K 5.07 0001193125-23-178604 001-41583 231057579 34 152557 1 1
2023-06-12 8-K 8-K 7.01,9.01 0001193125-23-165406 001-41583 231008905 34 183521 1 1
2023-05-23 8-K 8-K 8.01 0001193125-23-151872 001-41583 23949448 34 148724 1 1
2023-05-19 DEFA14A DEFA14A 0001193125-23-149413 001-41583 23940966 34 95606
2023-05-19 ARS ARS 0001193125-23-149397 001-41583 23940835 34 1041526
2023-05-19 DEF 14A DEF 14A 0001193125-23-149377 001-41583 23940725 34 484243
2023-05-16 8-K 8-K 7.01,8.01,9.01 0001193125-23-145650 001-41583 23925590 34 1183923 1 1
2023-05-12 424B4 424B4 0001193125-23-143489 333-268482 23915939 33 142821
2023-05-10 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-23-137754,2023-05-10 9999999995-23-001362 333-268482 23908608 33 1704
2023-05-10 10-Q 10-Q 0000950170-23-020076 001-41583 23904319 34 5939869 1 1
2023-05-10 8-K 8-K 2.02,9.01 0000950170-23-020073 001-41583 23904310 34 409828 1 1
2023-05-08 POS AM POS AM 0001193125-23-137754 333-268482 23896083 33 217197
2023-05-01 10-K/A 10-K/A 0001193125-23-130647 001-41583 23874982 34 501335 1 1
2023-04-14 S-8 S-8 0001193125-23-102073 333-271264 23821290 33 89487
2023-03-29 10-K 10-K 0000950170-23-010599 001-41583 23775276 34 11287527 1 1
2023-03-29 8-K 8-K 2.02,9.01 0000950170-23-010589 001-41583 23775191 34 380859 1 1
2023-03-22 8-K 8-K 1.01 0001193125-23-076795 001-41583 23753601 34 151781 1 1
2023-03-21 8-K 8-K 7.01,9.01 0001193125-23-075260 001-41583 23747854 34 6779868 1 1
2023-03-13 8-K 8-K 7.01 0001193125-23-068453 001-41583 23725658 34 148187 1 1
2023-03-01 8-K 8-K 5.02 0001193125-23-056314 001-41583 23693489 34 148283 1 1
2023-03-01 4 xslF345X03/ownership.xml 0001493152-23-006392 5292
2023-03-01 4 xslF345X03/ownership.xml 0001493152-23-006390 5289
2023-03-01 4 xslF345X03/ownership.xml 0001493152-23-006389 5222
2023-02-14 SC 13G/A formsc13ga.htm 0001493152-23-004955 005-93853 23630419 34 84006
2023-02-14 SC 13G formsc13g.htm 0001493152-23-004869 005-93853 23628877 34 90510
2023-01-25 8-K 8-K 8.01 0000950170-23-001185 001-41583 23553147 34 173247 1 1
2023-01-17 4/A xslF345X03/ownership.xml 0001493152-23-001702 4625
2023-01-05 SC 13G formsc13g.htm 0001493152-23-000441 005-93853 23509780 34 103032
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000227 8087
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000226 11046
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000225 6972
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000223 6958
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000224 6902
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000222 6964
2023-01-04 4 xslF345X03/ownership.xml 0001493152-23-000221 6844
2022-12-30 424B4 424B4 0001564590-22-040078 333-268482 221502162 33 9110075
2022-12-29 CERT 8A_Cert_COYA.pdf 0001354457-22-000801 001-41583 221496959 34 217245
2022-12-28 SEC STAFF LETTER filename1.pdf 9999999997-22-005061 274880
2022-12-28 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2022-12-28 17:15:00 9999999995-22-003654 333-268482 221496252 33 1692
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036723 3863
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036718 12360
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036717 14269
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036714 12688
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036713 13908
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036712 13244
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036711 12622
2022-12-28 3 xslF345X02/ownership.xml 0001493152-22-036709 13163
2022-12-27 8-A12B 8-A12B 0000950123-22-012756 001-41583 221490433 34 35598
2022-12-23 CORRESP filename1.htm 0001564590-22-039680 15284
2022-12-23 CORRESP filename1.htm 0001564590-22-039678 16197
2022-12-13 CORRESP filename1.htm 0001564590-22-039244 122548
2022-12-13 S-1/A S-1/A 0001564590-22-039242 333-268482 221458154 33 9827861
2022-12-09 UPLOAD filename1.pdf 0000000000-22-013298 44365
2022-12-06 FWP FWP 0001564590-22-039079 333-268482 221447995 34 12661359
2022-12-05 CORRESP filename1.htm 0001564590-22-038994 29934
2022-12-05 S-1/A S-1/A 0001564590-22-038993 333-268482 221443806 33 11672581
2022-11-29 UPLOAD filename1.pdf 0000000000-22-012862 45690
2022-11-23 SEC STAFF LETTER filename1.pdf 9999999997-22-004838 276163
2022-11-18 CORRESP filename1.htm 0001564590-22-038043 37708
2022-11-18 S-1 S-1 0001564590-22-038040 333-268482 221402724 33 13985072
2022-11-04 UPLOAD filename1.pdf 0000000000-22-012032 46682
2022-10-28 DRSLTR filename1.htm 0000950123-22-010566 50105
2022-10-28 DRS/A filename1.htm 0000950123-22-010565 377-06324 221343051 33 10134401
2022-10-19 UPLOAD filename1.pdf 0000000000-22-011498 50881
2022-10-07 DRSLTR filename1.htm 0000950123-22-010098 145326
2022-10-07 DRS/A filename1.htm 0000950123-22-010095 377-06324 221301192 33 7329805
2022-09-15 UPLOAD filename1.pdf 0000000000-22-010127 81581
2022-08-19 DRS filename1.htm 0001564590-22-029826 377-06324 221181355 33 6229347
2022-05-20 D xslFormDX01/primary_doc.xml 06b 0001493152-22-014555 021-446377 22946228 33 14517
2021-01-05 D xslFormDX01/primary_doc.xml 06b 0001835022-21-000001 021-385191 21503341 33 10520

Latest XBRL company facts

One latest value per concept from companyfacts (152 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 23.46M 2026-11-05 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
dei EntityPublicFloat Entity Public Float USD 89.42M 2025-06-30 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.45M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 913,675 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 723,852 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.78M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 285,120 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 98,216 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 119.99M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 910,076 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 4.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 997,367 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 4.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap Assets Assets USD 39.32M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap AssetsCurrent Assets, Current USD 39.07M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 35.80M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 35.80M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD -11.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 23.46M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 23.46M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap CommonStockValue Common Stock, Value, Issued USD 2,346 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 1.52B 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 729.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 12.97M 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD -718,582 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 3,089 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredFinanceCostsNoncurrentNet Debt Issuance Costs, Noncurrent, Net USD 1.12M 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap DeferredRevenue Deferred Revenue USD 0 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 1.16M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 271,294 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 60 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 5.98M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 1.90M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 645,393 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 13.31M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 60 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD -469 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap Depreciation Depreciation USD 8,421 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.05 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.05 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.244 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.005 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.067 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 4.50M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances USD 12.97M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) USD 2.50M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 12.97M 2022-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap FederalIncomeTaxExpenseBenefitContinuingOperations Federal Income Tax Expense (Benefit), Continuing Operations USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 8.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -24.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap IncomeTaxesPaid Income Taxes Paid USD 700,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD -730,581 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current USD 730,581 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 3,089 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD -725,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReceivable Income Taxes Receivable USD 700,000 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 5.18M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -4.46M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 103,368 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -775 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 36,708 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 1.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 1.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -959,216 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -729,026 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 120,441 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-11 0001193125-26-343481
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 151,827 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap LaborAndRelatedExpense Labor and Related Expense USD 1.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap Liabilities Liabilities USD 5.75M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 39.32M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap LiabilitiesCurrent Liabilities, Current USD 5.39M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 10.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -909,896 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -20.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -24.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OperatingExpenses Operating Expenses USD 26.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -25.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 43,139 2025-12-31 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 244,727 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OtherGeneralAndAdministrativeExpense Other General and Administrative Expense USD 3.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 1.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 140,428 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 2.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap PaymentsForRepurchaseOfInitialPublicOffering Payments for Repurchase of Initial Public Offering USD 341,901 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap PaymentsForRepurchaseOfPrivatePlacement Payments for Repurchase of Private Placement USD 65,385 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-10 0000950170-23-020076
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 997,367 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 244,727 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PaymentsToAcquireInProcessResearchAndDevelopment Payments to Acquire in Process Research and Development USD 909,896 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 10.04M 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 8.79M 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.27M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PrepaidInsurance Prepaid Insurance USD 205,038 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 10.47M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 14.25M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 10.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 38,274 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 2.14M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -24.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 136,804 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2,807 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Research and Development Expense (Excluding Acquired in Process Cost) USD 17.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 525,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -86.43M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap Revenues Revenues USD 729,026 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 4.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price USD/shares 3.48 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.003 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.039 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 1.74M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 2.63M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 5.19 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 3,438 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 211 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 922,428 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 1.95M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 3.89M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 5.28 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 1.95M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 3.89M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 5.28 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.09 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 1.09 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 4.77 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 30,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010599
us-gaap StateAndLocalIncomeTaxExpenseBenefitContinuingOperations State and Local Income Tax Expense (Benefit), Continuing Operations USD 3,089 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 33.57M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.176 2022-12-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033161
us-gaap StockholdersEquityNoteSubscriptionsReceivable Stockholders' Equity Note, Subscriptions Receivable USD 11,250 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-040782
us-gaap StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services shares 10,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107281
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 666 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 4.94M 2024-04-01 2024-06-30 2025 Q3 10-Q 2025-11-12 0001193125-25-276058
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 19,137 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 23.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 23.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454478

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →